Social Media

From narrow volume windows to SGLT2 inhibitors and emerging devices, Drs Kevin Alexander and Sarah Cuddy discuss heart failure care in ATTR-CM. Relevant…

Intellia said the FDA lifted the clinical hold on its heart-disease gene-editing trial for transthyretin amyloidosis, a rare condition caused by buildup of a faulty…

Clinical examination, search for extracardiac involvement, ECG… Dr. Nicolas Cabaye, member of the CCF, questions Dr. Antoine Jobbé-Duval on the initial assessment…

Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience significant quality of life challenges that extend beyond cardiac symptoms, including…

Attruby Emerges as a Compelling Alternative to Vyndamax in Cardiac Amyloidosis Treatment. Read now at PatientWorthy.com#PatientWorthy #VYNDAMAX #ATTR-COM #…

The Christ Hospital Heart & Vascular Institute is honored to host an Amyloidosis Support Group event on Saturday, Sept. 19, 2026, bringing together patients,…

Transthyretin cardiac amyloidosis (ATTR-CA) is gaining more attention—but many patients are still diagnosed later than they should be.At #ACC26, our partners @…

The availability of new and effective therapies such as gene stabilizers and silencers is changing the outlook for patients with transthyretin cardiac amyloidosis (…

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient…

Hi, could I ask those with cardiac involvement, when did your cardiac symptoms first start please? Thank you